[NOTE: DNA Business: A Gene Gold Rush available until October 5, 2026.]

What if the most intimate information about who we are had become a commodity?

Once the exclusive preserve of elite scientists and medical laboratories, DNA can now be decoded by anyone — with a simple home testing kit. A handful of tech start-ups, including Ancestry, 23andMe and MyHeritage, have turned our desire to know where we come from, who we are related to and what diseases we might be vulnerable to into a global, highly lucrative business.

But how reliable are the answers these companies provide? Behind the seductive promise of discovering our origins or predicting our health risks lie methods whose scientific validity is questioned by leading geneticists. And there is an even bigger issue: what happens to our DNA once we have handed it over?

In 2019, an estimated 26 million people worldwide had taken a direct-to-consumer DNA test. By the end of 2026, that figure is expected to have nearly doubled, reaching close to 50 million. Many believe they are simply buying information about themselves. Few realize that their genetic data can become a valuable asset — collected, stored and potentially sold to pharmaceutical companies to fuel medical research and drug development. Regulation is struggling to keep pace. In some countries, certain insurers can already consider genetic-test results when deciding whom to cover—and at what price. Could other financial institutions one day seek access to the same extraordinarily sensitive information?

Through compelling personal stories, undercover investigation and interviews with leading geneticists, researchers and lawyers, this film exposes the hidden economy growing around our DNA.

This is no longer simply a story about science. It is a story about privacy, identity, money and power — and about the extraordinary possibility that, in the future, our genes could determine not only who we are, but how the world treats us.